2017 American Transplant Congress
Reassessing Thymoglobulin Induction in Kidney Transplantation (RETHINK): An Analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry.
There is no consensus on Thymoglobulin (TMG) dose used for induction immunosuppression (IS) in pediatric kidney transplants (KTx). We aimed to identify: 1) TMG induction…2017 American Transplant Congress
Induction Immunotherapy in ECD and DGF Kidneys: Does ECD Equal Diminishing Induction Returns?
University of Michigan, Ann Arbor
The benefit of induction immunotherapy to prevent DGF or mitigate its effects in recipients of marginal kidneys is not well understood and practices vary. We…2017 American Transplant Congress
Induction Therapy in Low Risk Elderly Kidney Transplant Recipients: Donor Factors.
Johns Hopkins, Baltimore; University of Colorado, Denver
It is not known whether depleting induction is needed in low-risk elderly kidney transplant (KT) recipients in whom concern for infectious and complications is higher…2017 American Transplant Congress
Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin (rATG) 3mg/kg vs. 6mg/kg in Kidney Transplant Patients Under Steroid-Free and CNI Minimization Maintenance Immunosuppressive Regimen.
Hospital Geral de Fortaleza, Fortaleza, Brazil
Background: rATG dosed from 4.5 to 7.5mg/kg has been the standard of care in most transplant centers. Recent studies have demonstrated similar efficacy with doses…2017 American Transplant Congress
Five Year Outcomes with Alemtuzumab Induction Therapy in Elderly Renal Transplant Recipients.
Pharmacy, Northwestern Memorial Hospital, Chicago, IL
Background:The elderly population (≥ 65 years) comprise one fourth of patients on the waiting list for renal transplantation. Alemtuzumab use has increased over the past…2017 American Transplant Congress
Induction in the Elderly: A Comparison of Basiliximab versus Rabbit Anti-Thymocyte Globulin After Kidney Transplantation.
Weill Cornell Medical Center, New York, NY
Background: Although it is well established that kidney transplant (KT) in the elderly is beneficial and safe, there is limited literature on the appropriate choice…2017 American Transplant Congress
Impact of Alemtuzumab Induction on Hepatitis C Treatment Outcomes Post-Renal Transplantation.
University of Maryland Medical Center, Baltimore, MD
BackgroundDirect-acting antiviral agents (DAAs) have improved treatment outcomes for Hepatitis C virus (HCV). Given high rates of treatment success with few side effects, eradication of…2017 American Transplant Congress
Induction Treatment with Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplant Recipients with Planned Early Steroid Withdrawal.
Transplant Surgery, Brigham and Women's Hospital, Boston
Introduction: In a previous study by our group, rabbit antithymocyte globulin (r-ATG) induction was associated with lower rates of rejection when compared to basiliximab in…2017 American Transplant Congress
IL-7 Receptor Heterogeneity as a Mechanism for Repertoire Change During Post-Depletional Homeostatic Proliferation and Its Relation to Costimulation Blockade Resistant Rejection.
Department of Surgery, Duke University School of Medicine, Durham, NC
Transplant patients treated with belatacept without depletional induction show high rates of costimulation blockade resistant rejection (CoBRR); this has been associated with CD57+ T cells.…2017 American Transplant Congress
The Impact of Induction Therapy on Delayed Graft Function Following Kidney Transplantation in Mated Kidneys.
Department of Transplantation, Albert Einstein-Montefiore, Bronx, NY
Purpose: Delayed graft function (DGF) is defined as the need for dialysis within one week of transplantation and occurs in 20-50% of deceased-donor kidney transplant…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 31
- Next Page »